Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
The DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index.
Abstract
Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters. Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small molecules. This Review discusses the role of altered expression and/or function of one class of epigenetic regulators--histone deacetylases (HDACs)--and their role in cancer, neurological diseases and immune disorders. We highlight the development of small-molecule HDAC inhibitors and their use in the laboratory, in preclinical models and in the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is increasing evidence that KDAC inhibitors work best in combination with other therapies [28–30]”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [29]
In the citing paper
“Growing evidence supports that epigenetic dysregulation through histone deacetylases (HDACs) plays a critical role in synaptic dysfunction and memory loss in Alzheimer’s disease”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDACs are epigenetic modulators that deacetylate lysine residues in histone and nonhistone substrates and their inhibition has attracted much interest for the treatment of neurodegenerative disorders, as several isoforms seem to be implicated in AD memory-related dysfunction: HDAC2 is a nuclear isoform that reduce transcription of CREB-regulated genes involved in learning and memory, HDAC6 targets”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [118]
Citations
Cites
4 retracted
Zhang, X., Zhao, X., Fiskus, W., Lin, J., Lwin, T., Rao, R., Zhang, Y., Chan, J. C., Fu, K., Marquez, V. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.003 · Cited by 276
RetractedChen, C.-S., Wang, Y.-C., Yang, H.-C., Huang, P.-H., Kulp, S. K., Yang, C.-C., Lu, Y.-S., Matsuyama, S., Chen, C.-Y., & Chen, C.-S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3996 · Cited by 187
RetractedDasmahapatra, G. P., Lembersky, D., Kramer, L. B., Fisher, R. I., Friedberg, J. W., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 115
RetractedDasmahapatra, G. P., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 62
RetractedChromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 3×
“AML1 and the AML1–ETO fusion protein in the pathogenesis of t(8;21) AML.”
BackgroundLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Cited by
Items 901–1,000 of 1,003
Chen, X., Gong, G., Chen, X., Song, R., Duan, M., Qiao, R., Jiao, Y., Qi, J., Chen, Y., & Zhu, Y. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00425 · Cited by 17
New perspectives for selective NCX activators in neurodegenerative diseases
Annunziato, L., Secondo, A., Pignataro, G., Scorziello, A., & Molinaro, P. (2020) · Cell Calcium · doi:10.1016/j.ceca.2020.102170 · Cited by 17
HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML
Huang, F., Sun, J., Chen, W., He, X., Zhu, Y., Dong, H., Wang, H., Li, Z., Zhang, L., Khaled, S. K., et al. (2020) · Aging · doi:10.18632/aging.103605 · Cited by 20
“HDACs catalyze removal of acetyl groups from histones or non-histone proteins, resulting in chromatin condensation and transcriptional repression [13].”
BackgroundInfluentialRole of histone deacetylases in bone development and skeletal disorders
Wang, J. S., Yoon, S.-H., & Wein, M. N. (2020) · Bone · doi:10.1016/j.bone.2020.115606 · Cited by 23
“Abnormal HDACs have been reported to play important roles in many human diseases including cancer, neurological disease, inflammatory and immune disorder, metabolic syndrome, cardiac disorder and pulmonary disease [14, 15].”
BackgroundMarek, M., Ramos‐Morales, E., Picchi, G. F. A., Bayer, T., Norström, C., Herp, D., Sales-Junior, P. A., Guerra-Slompo, E. P., Hausmann, K., Chakrabarti, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110129 · Cited by 18
Expanding the Genetic Code to Study Protein–Protein Interactions
Nguyen, T., Cigler, M., & Lang, K. (2018) · Angewandte Chemie · doi:10.1002/ange.201805869 · Cited by 17
Ren, Y., Sun, Q., Yuan, Z., & Jiang, Y. (2019) · Chinese Chemical Letters · doi:10.1016/j.cclet.2019.03.029 · Cited by 17
Hulin-Curtis, S. L., Davies, J. A., Jones, R., Hudson, E., Hanna, L., Chester, J. D., & Parker, A. L. (2018) · Oncotarget · doi:10.18632/oncotarget.25242 · Cited by 18
“HDAC inhibitors (HDACis) block histone deacetylation, promote cancer cell death and an immunogenic response [31].”
BackgroundRecent Study of Dual HDAC/PARP Inhibitor for the Treatment of Tumor
Lu, H., Bai, L., Zhou, Y., Lu, Y., Jiang, Z., & Shi, J. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190603092407 · Cited by 18
PWWP2B Fine‐Tunes Adipose Thermogenesis by Stabilizing HDACs in a NuRD Subcomplex
Yan, L., Jin, W., Zhao, Q., Cui, X., Shi, T., Xu, Y., Li, F., Jin, W., Zhang, Z., Zhang, Z., et al. (2021) · Advanced Science · doi:10.1002/advs.202102060 · Cited by 16
Zhu, X., Li, J., You, D., Xiao, Y., Huang, Z., & Yu, W. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02880-w · Cited by 16
“Histone deacetylases (HDACs) are widely known as a family of enzymes, that possess the ability to catalyze the removal of acetyl groups from the acetyl-lysine residues in histone and non-histone proteins [13], and often function as epigenetic regulators involved in the pathological processes of malignancies, neurologi…”
BackgroundBae, J.-E., Kim, J. B., Jo, D. S., Park, N. Y., Kim, Y. H., Lee, H. J., Kim, S. H., Ys, K., Son, M., Kim, P., et al. (2022) · Cells · doi:10.3390/cells11172722 · Cited by 17
“the lysine residues of the histone proteins, resulting in the epigenetic modulation of gene expression [22,23].”
BackgroundPeter, R. M., Sarwar, M. S., Mostafa, S. Z., Wang, Y., Su, X., & Kong, A. T. (2023) · Molecular Carcinogenesis · doi:10.1002/mc.23551 · Cited by 17
Zhang, W., Ge, L., Zhang, Y., Zhang, Z., Zhang, W., Song, F., Huang, P., & Xu, T. (2025) · European journal of medical research · doi:10.1186/s40001-025-02326-8 · Cited by 25
Musso, L., Cincinelli, R., Zuco, V., Zunino, F., Nurisso, A., Cuendet, M., Giannini, G., Vesci, L., Pisano, C., & Dallavalle, S. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.09.006 · Cited by 16
Ruess, D. A., Probst, M., Marjanović, G., Wittel, U. A., Hopt, U. T., Keck, T., & Bausch, D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161233 · Cited by 17
Exploiting histone deacetylases for cancer therapy: from hematological malignancies to solid tumors
Huang, M., & Geng, M. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-0300-y · Cited by 15
Becker, L., Nogueira, M. S., Klima, C., de Angelis, M. H., & Peleg, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-22674-2 · Cited by 16
Isotopic Labeling and Quantitative Proteomics of Acetylation on Histones and Beyond
Lund, P. J., Kori, Y., Zhao, X., Sidoli, S., Yuan, Z., & Garcia, B. A. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9232-4_5 · Cited by 16
Chromatin modification and epigenetic control in functional nerve regeneration
Berry, K., & Lu, Q. R. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.07.009 · Cited by 18
Kashyap, K., & Kakkar, R. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1711191 · Cited by 17
Campit, S., Meliki, A., Youngson, N. A., & Chandrasekaran, S. (2020) · BioEssays · doi:10.1002/bies.202000083 · Cited by 23
Yano, M., Miyazawa, M., Ogane, N., Ogasawara, A., Hasegawa, K., Narahara, H., & Yasuda, M. (2021) · Anticancer Research · doi:10.21873/anticanres.14927 · Cited by 17
“Histone deacetylases (HDACs), which comprise 18 subtypes identi ed in humans, regulate tissue differentiation, apoptosis, migration, mitosis, and angiogenesis by chromatin-modi cation via the deacetylation of histone or non-histone proteins [7].”
BackgroundLamoine, S., Cuménal, M., Barrière, D. A., Pereira, V., Fereyrolles, M., Prival, L., Barbier, J., Boudieu, L., Brasset, É., Bertin, B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010098 · Cited by 20
“Furthermore, HDAC inhibitors are promising therapeutic molecules against several pathological states, including cancer [25].”
BackgroundThe Multiple Myeloma Landscape: Epigenetics and Non-Coding RNAs
Coira, I. F., Rincón, R., & Cuendet, M. (2022) · Cancers · doi:10.3390/cancers14102348 · Cited by 16
“Their targets include histones but also non-histone proteins such as p53, Hsp90, and p65 NF-κB [23].”
BackgroundHao, C., Hu, Z., Kang, Y., Huang, J., Wu, Y., Chen, Q., Wei, R., Wang, P., Wang, H., Li, H., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114484 · Cited by 16
Regulation of Histone Deacetylases by MicroRNAs in Bone
Shreya, S., Malavika, D., Priya, V. R., & Selvamurugan, N. (2018) · Current Protein and Peptide Science · doi:10.2174/1389203720666181031143129 · Cited by 17
Epigenetic Risk Profile of Diabetic Kidney Disease in High-Risk Populations
Xu, L., Natarajan, R. D., & Chen, Z. B. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1129-2 · Cited by 16
Ma, X., Xu, G., Li, Z., Chen, F., Wu, D., Miao, J., Zhan, Y., & Fan, Y. (2019) · Current Medical Science · doi:10.1007/s11596-019-2024-4 · Cited by 17
Yang, F., Sun, S., Wang, C., Haas, M., Yeo, S. K., & Guan, J. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0839-1 · Cited by 16
Emerging biological therapies for the treatment of myelodysplastic syndromes
Zeidan, A. M., Stahl, M. F., & Komrokji, R. S. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1220534 · Cited by 15
Taha, T. Y., Anirudhan, V., Limothai, U., Loeb, D. D., Petukhov, P. A., & McLachlan, A. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008802 · Cited by 16
“HDACs play a pleiotropic role in cellular homeostasis with the different isoforms regulating unique cellular functions [18,21].”
BackgroundGarcia‐Manero, G., Kaźmierczak, M., Wierzbowska, A., Fong, C. Y., Keng, M. K., Ballinari, G., Scarci, F., & Adès, L. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107480 · Cited by 17
Could targeting epigenetic processes relieve chronic pain states?
Géranton, S. M., & Tochiki, K. K. (2015) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000127 · Cited by 19
Lupiañez, C. B., Villaescusa, M. T. L., Carvalho, A., Springer, J., Lackner, M., Sánchez‐Maldonado, J. M., Canet, L. M., Cunha, C., Segura-Catena, J., Alcázar‐Fuoli, L., et al. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01243 · Cited by 19
The epigenetic regulation of Dicer and microRNA biogenesis by Panobinostat
Hoffend, N. C., Magner, W. J., & Tomasi, T. B. (2016) · Epigenetics · doi:10.1080/15592294.2016.1267886 · Cited by 19
Ultralong circulating choline phosphate liposomal nanomedicines for cascaded chemo-radiotherapy
Li, X., Zhao, Y., Jiang, W., Li, S., Zhan, M., Liu, H., Zhang, C., Liang, H., Liu, H., Lu, L., et al. (2019) · Biomaterials Science · doi:10.1039/c9bm00051h · Cited by 15
Nham, G. T. H., Zhang, X., Asou, Y., & Shinomura, T. (2019) · Gene · doi:10.1016/j.gene.2019.04.034 · Cited by 15
Bitzer, M., & Malek, N. P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00042-9 · Cited by 15
Selg, C., Schöler, A., Schliehe‐Diecks, J., Hanl, M., Sinatra, L., Borkhardt, A., Sárosi, M. B., Bhatia, S., Hey‐Hawkins, E., & Hansen, F. K. (2021) · Chemical Science · doi:10.1039/d1sc02268g · Cited by 16
HDAC7 inhibits cell proliferation via NudCD1/GGH axis in triple‑negative breast cancer
Zhu, M., Liu, N., Lin, J., Wang, J., Lai, H., & Liu, Y. (2022) · Oncology Letters · doi:10.3892/ol.2022.13619 · Cited by 15
“It has been reported that multiple HDACs including HDAC1/2/3/6 are dysregulated in BRCA and participate in BRCA progression, metastasis and invasion (12,15,16).”
A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity
Falkenberg, K. J., Newbold, A., Gould, C., Luu, J., Trapani, J. A., Matthews, G. M., Simpson, K. J., & Johnstone, R. W. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2015.175 · Cited by 15
Self-citationCortopassi, W. A., Kumar., K., V, Duarte, F., Pimentel, A. S., & Paton, R. S. (2016) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2016.04.011 · Cited by 18
Tambo, Y., Hosomi, Y., Sakai, H., Nogami, N., Atagi, S., Sasaki, Y., Kato, T., Takahashi, T., Seto, T., Maemondo, M., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0435-2 · Cited by 16
Zhang, M., Ying, J. B., Wang, S., He, D., Zhu, H., Zhang, C., Tang, L., Lin, R., & Zhang, Y. (2020) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29583 · Cited by 15
Kashyap, K., & Kakkar, R. (2020) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.103850 · Cited by 18
Brosowsky, J., Lutterbeck, M., Liebich, A., Keller, M., Herp, D., Vogelmann, A., Jung, M., & Breit, B. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202002449 · Cited by 15
PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance
Giardina, S. F., Valdambrini, E., Warren, J. D., & Barany, F. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210203110857 · Cited by 15
A lineage tree-based hidden Markov model quantifies cellular heterogeneity and plasticity
Mohammadi, F., Visagan, S., Gross, S. M., Karginov, L., Lagarde, J. C., Heiser, L. M., & Meyer, A. S. (2022) · Communications Biology · doi:10.1038/s42003-022-04208-9 · Cited by 19
“6, 7).”
Guo, T., Hu, S., Xu, W., Zhou, J., Chen, F., Gao, T., Qu, W., Chen, F., Lv, Z., & Lü, L. (2023) · iScience · doi:10.1016/j.isci.2023.106882 · Cited by 15
“28 (days of gathering the sample after birth) (2-33) (4-101) Enteral feeds 1.”
BackgroundAbdulwahab, H. G., Mansour, R. E., Farghaly, T. A., & El-Sehrawi, H. M. A. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107284 · Cited by 16
HDAC inhibitor enhances ferroptosis susceptibility of AML cells by stimulating iron metabolism
Bian, R., Shang, Y., Xu, N., Liu, B., Ma, Y., Li, H., Chen, J., & Yao, Q. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111583 · Cited by 16
Preclinical studies of 5-fluoro-2′-deoxycytidine and tetrahydrouridine in pediatric brain tumors
Morfouace, M., Nimmervoll, B. V., Boulos, N., Patel, Y. T., Shelat, A. A., Freeman, B. B., Robinson, G. W., Wright, K. D., Gajjar, A. J., Stewart, C. F., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1965-0 · Cited by 14
Zabkiewicz, J., Hodges, M., Hills, R. K., Vyas, P., Bone, E., Davidson, A. H., Burnett, A. K., & Knapper, S. (2016) · Oncotarget · doi:10.18632/oncotarget.7692 · Cited by 14
Takada, K., Imae, Y., Ise, Y., Ohtsuka, S., Ito, A., Okada, S., Yoshida, M., & Matsunaga, S. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.6b00588 · Cited by 13
Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?
Virmani, P., Hwang, S., Hastings, J. G., Haverkos, B. M., Kohnken, R. A., Gru, A. A., Mishra, A., Fabbro, S. K., Horwitz, S. M., & Porcu, P. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2017.1270201 · Cited by 16
Mertsch, S., & Krämer, O. H. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.05.006 · Cited by 15
Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1
Gendarme, M., Baumann, J., Ignashkova, T. I., Lindemann, R. K., & Reiling, J. H. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-03-0176 · Cited by 15
“Moreover, HDACi treatment can lead to reactive oxygen species (ROS) generation, thereby contributing to proapoptotic signaling (Falkenberg and Johnstone, 2014).”
BackgroundValle, N. R.-D., Cheng, T., Irwin, M. E., Donnella, H. J., Singh, M. M., & Chandra, J. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3509-0 · Cited by 14
“Preclinical studies have well documented that HDACi exert their anti-cancer effects through various mechanisms given the broad regulatory targets of HDACi [8].”
BackgroundTumour Expression of Histone Deacetylases in Uveal Melanoma
Levinzon, L., Madigan, M. C., Nguyen, V., Hasic, E., Conway, M., & Cherepanoff, S. (2018) · Ocular Oncology and Pathology · doi:10.1159/000490038 · Cited by 12
Epigenetics and Common Non Communicable Disease
Tabatabaiefar, M. A., Sajjadi, R. S., & Narrei, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-10616-4_2 · Cited by 15
Zhang, K., Yao, Y., Tu, Z., Liao, C., Wang, Z., Qiu, Y., Chen, D., Hamilton, D. J., Li, Z., & Jiang, S. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0290 · Cited by 14
O-Alkyl Hydroxamates Display Potent and Selective Antileishmanial Activity
Corpas‐López, V., Tabraue-Chávez, M., Sixto‐López, Y., Panadero-Fajardo, S., Franco, F. A. D. L., Domínguez-Seglar, J. F., Morillas‐Márquez, F., Franco-Montalbán, F., Díaz‐Gavilán, M., Correa‐Basurto, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02016 · Cited by 15
Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma
Müller, M., Rösch, L., Najafi, S., Gatzweiler, C., Ridinger, J., Gerloff, X. F., Jones, D. T. W., Baßler, J., Kreth, S., Stainczyk, S., et al. (2021) · Cancers · doi:10.3390/cancers13174476 · Cited by 14
Villares, R., Gutiérrez, J., Fütterer, A., Trachana, V., del Burgo, F. G., & Martínez‐A, C. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419300112 · Cited by 14
Ota, S., Zhou, Z.-Q., Romero, M. P., Yang, G., & Hurlin, P. J. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw255 · Cited by 14
Deciphering the Epigenetic Code in Embryonic and Dental Pulp Stem Cells.
Bayarsaihan, D. (2016) · PubMed Central · Cited by 16
A Comparative Study of Target Engagement Assays for HDAC1 Inhibitor Profiling
Asawa, R. R., Zakharov, A. V., Niehoff, T., Ata, C., Jadhav, A., Henderson, M. J., Simeonov, A. M., & Martinez, N. J. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219883625 · Cited by 14
“Therefore, the development of HDAC inhibitors has been an intensive area of research for the past two decades.(4,6) The majority of HDAC inhibitors lack selectivity and target all HDACs (pan-inhibitors) or a subset of HDACs (class-selective inhibitors).”
BackgroundGabano, E., Rangone, B., Perin, E., Caron, G., Ermondi, G., Vallaro, M., Gandin, V., Marzano, C., Barbanente, A., Margiotta, N., et al. (2021) · Dalton Transactions · doi:10.1039/d0dt04135a · Cited by 15
Minjie, S., Defei, H., Hu, Z., Weiding, W., & Zhang, Y. (2015) · Tumor Biology · doi:10.1007/s13277-015-3537-5 · Cited by 14
Roatsch, M., Vogelmann, A., Herp, D., Jung, M., & Olsen, C. A. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12416303.v1 · Cited by 16
Ramos, T. L., Sánchez-Abarca, L. I., Redondo, A., Hernández-Hernández, Á., Almeida, A. M., Puig, N., Rodríguez, C., Ortega, R., Preciado, S., Rico, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15969 · Cited by 13
“HDAC8 is a class I HDAC involved in various diseases, including cancer [11, 12].”
BackgroundTreatment options for patients with myelodysplastic syndromes after hypomethylating agent failure
Carraway, H. E. (2016) · Hematology · doi:10.1182/asheducation-2016.1.470 · Cited by 15
Update on the Treatment of Retinoblastoma
Manrique, M. M., Akinbolue, D., Madigan, W. P., & Bregman, J. A. (2021) · NeoReviews · doi:10.1542/neo.22-7-e423 · Cited by 13
Targeting histone deacetylases for heart diseases
Jin, G. Y., Wang, K., Zhao, Y., Yuan, S., He, Z., & Zhang, J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106601 · Cited by 17
HDAC8 As an Emerging Target in Drug Discovery With Special Emphasis on Medicinal Chemistry
Rajaraman, S., Balakrishnan, R., Deshmukh, D., Ganorkar, A., Biswas, S., Pulya, S., & Ghosh, B. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0054 · Cited by 16
Mo, H., Liu, J.-Y., Su, Z., Zhao, D., Ma, Y., Zhang, K., Wang, Q., Fu, C. M., Wang, Y., Chen, M., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116765 · Cited by 14
Khatun, S., Dasgupta, I., Sen, S., Amin, S. A., Qureshi, I. A., Jha, T., & Gayen, S. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.138119 · Cited by 13
Overview of the epigenetic/cytotoxic dual-target inhibitors for cancer therapy
Liang, H., Li, S., Peng, X., & Xiao, H. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117235 · Cited by 14
Lee, M. P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00794 · Cited by 13
“Vorinostat (SAHA), belinostat (PXD101), and romidepsin are FDA approved histone deacetylase (HDAC) inhibitors for cutaneous T cell lymphoma (CTCL) patients (73).”
BackgroundYang, H., Liu, Y., Liu, X., Gu, H., Zhang, J., & Sun, C. (2020) · Stem Cells International · doi:10.1155/2020/7618506 · Cited by 14
“At present, many small molecule inhibitors of KDACs and KATs have been attractive therapeutic candidates [38].”
BackgroundBian, L., Xu, F., & Jiang, Z. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000923 · Cited by 14
“Epigenetic alterations can be modulated or reversed by HDAC inhibitors.([24]) Tucidinostat (formerly known as chidamide) is an oral subtype-specific HDAC inhibitor that was independently developed in China and induces cell cycle arrest, differentiation, and death in cancer cells to alter the tumor microenvironment.”
BackgroundInduction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer
Wei, T.-T., Lin, Y.-C., Lin, P.-H., Shih, J., Chou, C., Huang, W., Yang, Y., Hsiao, P., & Chen, C. (2015) · Oncotarget · doi:10.18632/oncotarget.3489 · Cited by 13
Ekman, A., & Enerbäck, C. (2015) · British Journal of Dermatology · doi:10.1111/bjd.14021 · Cited by 13
Synthesis of a selective HDAC6 inhibitor active in neuroblasts
Zwick, V., Simões‐Pires, C. A., Nurisso, A., Petit, C., Passos, C. D. S., Randazzo, G. M., Martinet, N., Bertrand, P., & Cuendet, M. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.09.011 · Cited by 13
Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation
Hutt, D. M., Roth, D., Marchal, C., & Bouchecareilh, M. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6527-4_6 · Cited by 14
Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts
Ruess, D. A., Görgülü, K., Wörmann, S. M., & Algül, H. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0453-y · Cited by 15
Sun, X.-Y., Qu, Y., Ni, A.-R., Wang, G.-X., Huang, W.-B., Chen, Z., Lv, Z., Zhang, S., Lindsay, H., Zhao, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20744 · Cited by 15
“These enzymes remove acetyl groups from lysine on histones and other proteins [13].”
BackgroundUcar, D., & Benayoun, B. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-811060-7.00001-2 · Cited by 15
Mahindra, A., Millard, C. J., Black, I., Archibald, L. J., Schwabe, J. W. R., & Jamieson, A. G. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b00885 · Cited by 13
Dawood, M., Hegazy, M. F., Elbadawi, M., Fleischer, E., Klinger, A., Bringmann, G., Kuntner, C., Shan, L., & Efferth, T. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114176 · Cited by 13
Histone Deacetylase Inhibitors Are Protective in Acute but Not in Chronic Models of Ototoxicity
Yang, C., Liu, Z., Dong, D., Schacht, J., Arya, D. P., & Sha, S. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00315 · Cited by 13
“For example, deficient histone acetylation is found in cancer and progressive neurodegenerative diseases, such as Parkinson and Alzheimer’s diseases (Falkenberg and Johnstone, 2014).”
Identifying Small‐Molecule Binding Sites for Epigenetic Proteins at Domain–Domain Interfaces
Bowkett, D., Talon, R., Tallant, C., Schofield, C. J., von Delft, F., Knapp, S., Bruton, G., & Brennan, P. E. (2018) · ChemMedChem · doi:10.1002/cmdc.201800030 · Cited by 13
Pinheiro, P. D. S. M., Diniz, L. P., Franco, L. S., Siqueira, M., & Gomes, F. C. A. (2025) · Pharmaceuticals · doi:10.3390/ph18101471 · Cited by 13
Felten, R., Ye, T., Schleiss, C., Schwikowski, B., Sibilia, J., Monneaux, F., Dumortier, H., Jonsson, R., Lessard, C. J., Ng, W., et al. (2023) · Rheumatology · doi:10.1093/rheumatology/kead096 · Cited by 13
Shanmugam, G., Subramaniyam, K., George, M., & Sarkar, K. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110661 · Cited by 14
Molecular origin and biological effects of exercise mimetics
Zhu, Y., & Song, G. (2023) · Journal of Exercise Science & Fitness · doi:10.1016/j.jesf.2023.12.002 · Cited by 17
“110 ⑨ Other molecular targets, such as androgens, have been found to be upregulated by exercise, promoting protein synthesis, skeletal muscle metabolism, and red blood cell production to promote overall health.”
BackgroundBiological characteristics and clinical management of uveal and conjunctival melanoma
Kaštelan, S., Pavičić, A. D., Pašalić, D., Nikuševa-Martić, T., Čanović, S., Kovačević, P., & Konjevoda, S. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.048437 · Cited by 12
“Histone deacetylases (HDAC) are enzymes responsible for epigenetic modi fi cations in cancer cells [164].”
BackgroundFrance, F. A. D. S., Maeda, D. K., Rodrigues, A. B., Ono, M., Marchetti, F. L. N., Marchetti, M. M., Martins, A. C. F., Gomes, R. D. S., & Rainho, C. A. (2024) · Epigenetics · doi:10.1080/15592294.2024.2400423 · Cited by 11
“Human HDACs have been implicated in the pathogenesis of cancer, diabetes, and immune and neurological diseases [44–46].”
BackgroundNiu, Z., Shi, Z., Wu, G., Liu, Y., Xie, W., Liu, F., Fan, T., Shu, K., Huang, Q., Dai, M., et al. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.108080 · Cited by 12
Metadata
- Authors
- Falkenberg, K. J., & Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-08-18
- Volume
- 13
- Issue
- 9
- Pages
- 673-691
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2046345187
- Cited by
- 1,564
- References
- 281
- Citations by year
- 2026: 82 · 2025: 110 · 2024: 89 · 2023: 96 · 2022: 121 · 2021: 133 · 2020: 160 · 2019: 146 · 2018: 134 · 2017: 166 · 2016: 208 · 2015: 108 · 2014: 8
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Update notices
- addendum (2015-02-27)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase, histone deacetylase inhibitors, epigenetic regulation, cancer, neurological disorders, immune disorders, small molecule inhibitors, lysine deacetylation, epigenetic aberrations, drug development
- MeSH terms
- Animals, Histone Deacetylases, Humans, Immune System Diseases, Neoplasms, Nervous System Diseases, Epigenesis, Genetic, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.